Qué hace esta calculadora
Organizes renal mass MRI features into the five-point clear cell likelihood score.
Enter the lesion's signal, enhancement, diffusion, and fat-related MRI features.
Antes del cálculo
- Confirm a predominantly solid enhancing renal mass without macroscopic fat and adequate multiparametric MRI.
- Review T2 signal, chemical shift, diffusion, and multiphasic enhancement using the same lesion throughout the decision tree.
Alcance clínico
Use ccLS to estimate the likelihood that an indeterminate, predominantly solid, enhancing renal mass without macroscopic fat represents clear cell renal cell carcinoma on multiparametric MRI. The original clinical context emphasized small renal masses.
Aplicabilidad y exclusiones
- Do not apply the score to a mass with macroscopic fat, a predominantly cystic mass, or a lesion with less than the required enhancing solid tissue.
- ccLS estimates subtype likelihood; it is not a Bosniak category, pathologic diagnosis, stage, grade, or management recommendation.
Método y lógica de cálculo
The algorithm first checks macroscopic fat and adequate enhancement, then evaluates T2 signal and corticomedullary enhancement. Microscopic fat, segmental enhancement inversion, diffusion restriction, and enhancement behavior refine the five-point likelihood score.
Tabla de interpretación
| Score | Likelihood of clear cell RCC |
|---|---|
| 1 | Very unlikely |
| 2 | Unlikely |
| 3 | Indeterminate / equivocal |
| 4 | Likely |
| 5 | Highly likely |
Errores frecuentes
- Applying ccLS to a predominantly cystic or Bosniak-pathway lesion, macroscopic-fat lesion, or inadequately enhancing mass.
- Treating a high score as pathologic confirmation or a stand-alone management recommendation.
ccLS estimates the imaging likelihood of clear cell RCC; it does not establish subtype, grade, stage, or treatment.
Ejemplo práctico
Caso: Fictional example: a 3 cm solid enhancing renal mass has no macroscopic fat, is T2 hyperintense, and shows intense corticomedullary enhancement without a downgrade feature.
Cálculo: Confirm eligibility, then follow the T2 signal and corticomedullary enhancement branches and enter any refinement features.
Interpretación: A high ccLS supports a higher likelihood of clear cell RCC but does not replace histopathology or multidisciplinary management.
Cómo usar esta calculadora
- Completa los campos visibles de imagen y medición. Los datos obligatorios están indicados en la herramienta.
- Revisa la categoría, la puntuación, las mediciones y cualquier recomendación o advertencia calculada.
- Copia el texto para el informe solo después de comprobar el resultado con la exploración completa y la guía de referencia.
Preguntas sobre esta calculadora
What population was ccLS developed for?
It was developed for indeterminate solid enhancing renal masses on multiparametric MRI, with much of the evidence centered on small renal masses and exclusion of macroscopic fat.
Does ccLS diagnose clear cell RCC?
No. It provides an imaging likelihood category. Histopathology remains the reference standard when tissue diagnosis is required.
¿Se envían las mediciones de pacientes a RadPhrases?
No. Los datos introducidos y los resultados se procesan en el navegador y esta página no los envía.